Get the Stockscreener App
11.69
2.26%
-0.27
After Hours:
11.69
Cullinan Therapeutics Inc stock is traded at $11.69, with a volume of 337.38K.
It is down -2.26% in the last 24 hours and up +10.18% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
See More
Previous Close:
$11.96
Open:
$12.03
24h Volume:
337.38K
Relative Volume:
0.34
Market Cap:
$690.60M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-3.168
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
-1.35%
1M Performance:
+10.18%
6M Performance:
+60.80%
1Y Performance:
+18.20%
1-Day Range:
$11.53
$12.34
1-Week Range:
$11.36
$12.55
52-Week Range:
$5.68
$13.43
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
11.69 | 706.55M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Aug-21-25 | Resumed | H.C. Wainwright | Buy |
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
CGEM: 2026 will deliver key data for T cell engagers in autoimmune and AML, driving major portfolio catalysts - TradingView
Retail Trends: Whats the profit margin of Cullinan Therapeutics IncProduct Launch & Intraday High Probability Alerts - baoquankhu1.vn
Cullinan Therapeutics (NASDAQ:CGEM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Guggenheim Upgrades Cullinan Therapeutics (NASDAQ:CGEM) to Strong-Buy - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month HighTime to Buy? - MarketBeat
Guggenheim Initiates Coverage of Cullinan Therapeutics (CGEM) with Buy Recommendation - Nasdaq
Guggenheim Initiates Coverage on CGEM with a 'Buy' Rating | CGEM Stock News - GuruFocus
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target By Investing.com - Investing.com UK
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers - Seeking Alpha
What is Cullinan Therapeutics Inc.’s valuation compared to sectorPortfolio Return Summary & Advanced Technical Analysis Signals - mfd.ru
Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? - Yahoo Finance
Aug Patterns: What drives Cullinan Therapeutics Incs stock price2025 Pullback Review & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Levels Update: What drives Cullinan Therapeutics Incs stock priceMarket Weekly Review & Low Risk High Reward Ideas - baoquankhu1.vn
Cullinan Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Cullinan Therapeutics, Inc. Rings the Opening Bell - Nasdaq
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $49,200.00 in Stock - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Is Cullinan Therapeutics (NASDAQ:CGEM) In A Good Position To Invest In Growth? - Sahm
Cullinan Therapeutics (NASDAQ:CGEM) Cut to "Sell" at Wall Street Zen - MarketBeat
Stocks to watch: Cullinan Therapeutics sees RS rating jump to 91 - MSN
Insider Sell: Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics Inc (CGEM) - GuruFocus
Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Gainers Report: Can Cullinan Therapeutics Inc outperform under higher oil prices2025 Support & Resistance & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength - Yahoo Finance
JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36 - 富途牛牛
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 10.6%Here's Why - MarketBeat
History Review: What is the Moat Score of Cullinan Therapeutics IncIPO Watch & Verified Momentum Stock Alerts - baoquankhu1.vn
Will Cullinan Therapeutics Inc benefit from AI trends2025 Market WrapUp & Risk Controlled Swing Alerts - baoquankhu1.vn
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 6.2%Here's What Happened - MarketBeat
Published on: 2026-01-11 22:17:06 - ulpravda.ru
Cullinan Therapeutics (CGEM) price target increased by 19.75% to 32.84 - MSN
Cullinan Therapeutics provides corporate update, anticipated 2026 milestones - Yahoo Finance
Market Fear: Will Cullinan Therapeutics Inc. stock split again soonWeekly Stock Report & Real-Time Volume Triggers - ulpravda.ru
Will Cullinan Therapeutics Inc. stock split again soonProfit Target & Weekly Return Optimization Alerts - ulpravda.ru
How strong is Cullinan Therapeutics Inc. stock balance sheetQuarterly Trade Review & Reliable Breakout Stock Forecasts - ulpravda.ru
Today's Analyst Ratings Update: CGEM Price Target Raised to $27 - GuruFocus
Cullinan Management Outlines Catalyst-Rich 2026 Pipeline Outlook - TipRanks
Cullinan Therapeutics (CGEM) Outlines Key Developments for 2026 - GuruFocus
Cullinan Therapeutics plans data readouts for key autoimmune programs By Investing.com - Investing.com Australia
Cullinan Therapeutics plans data readouts for key autoimmune programs - Investing.com India
Cullinan Therapeutics Outlines 2026 Milestones for CLN-978 and CLN-049 Programs, NDA Submission for Zipalertinib - Quiver Quantitative
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones - Chartmill
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 9.5%Here's Why - MarketBeat
Cullinan Therapeutics, Inc.Common Stock (NQ:CGEM) - FinancialContent
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):